These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26518895)

  • 41. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
    Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
    Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liver cancer stem cell markers: Progression and therapeutic implications.
    Sun JH; Luo Q; Liu LL; Song GB
    World J Gastroenterol; 2016 Apr; 22(13):3547-57. PubMed ID: 27053846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy.
    Rodriguez-Ramirez C; Nör JE
    Crit Rev Oncog; 2018; 23(3-4):173-187. PubMed ID: 30311573
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of targeted therapy on recruited cancer stem cells in a head and neck carcinoma model.
    Marcu LG; Marcu D
    Cell Prolif; 2017 Dec; 50(6):. PubMed ID: 28857306
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lung cancer stem cell: fancy conceptual model of tumor biology or cornerstone of a forthcoming therapeutic breakthrough?
    Sourisseau T; Hassan KA; Wistuba I; Penault-Llorca F; Adam J; Deutsch E; Soria JC
    J Thorac Oncol; 2014 Jan; 9(1):7-17. PubMed ID: 24346089
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer stem cells: implications for the progression and treatment of metastatic disease.
    Croker AK; Allan AL
    J Cell Mol Med; 2008 Apr; 12(2):374-90. PubMed ID: 18182063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-coding RNAs in drug resistance of head and neck cancers: A review.
    Dai F; Dai L; Zheng X; Guo Y; Zhang Y; Niu M; Lu Y; Li H; Hou R; Zhang Y; Wen S; Hu W; An C; Wu Y; Gao W
    Biomed Pharmacother; 2020 Jul; 127():110231. PubMed ID: 32428836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigational drugs for head and neck cancer.
    Bossi P; Alfieri S
    Expert Opin Investig Drugs; 2016 Jul; 25(7):797-810. PubMed ID: 27054910
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of Mesenchymal Stem/Stromal Cells in Head and Neck Cancer-Regulatory Mechanisms of Tumorigenic and Immune Activity, Chemotherapy Resistance, and Therapeutic Benefits of Stromal Cell-Based Pharmacological Strategies.
    Starska-Kowarska K
    Cells; 2024 Jul; 13(15):. PubMed ID: 39120301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In silico modelling of a cancer stem cell-targeting agent and its effects on tumour control during radiotherapy.
    Marcu LG; Marcu D
    Sci Rep; 2016 Aug; 6():32332. PubMed ID: 27573059
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In silico study of the impact of cancer stem cell dynamics and radiobiological hypoxia on tumour response to hyperfractionated radiotherapy.
    Marcu LG; Marcu D; Filip SM
    Cell Prolif; 2016 Jun; 49(3):304-14. PubMed ID: 27079860
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heterogeneity in cancer stem cells.
    Wang A; Chen L; Li C; Zhu Y
    Cancer Lett; 2015 Feb; 357(1):63-68. PubMed ID: 25444897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic and proteomic biomarkers of head-and-neck cancer: A systematic review.
    Kasradze D; Juodzbalys G; Guobis Z; Gervickas A; Cicciù M
    J Cancer Res Ther; 2020; 16(3):410-424. PubMed ID: 32719245
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting Head and Neck Cancer Stem Cells: Current Advances and Future Challenges.
    Birkeland AC; Owen JH; Prince ME
    J Dent Res; 2015 Nov; 94(11):1516-23. PubMed ID: 26307039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The cancer stem cell concept in progression of head and neck cancer.
    Chen ZG
    J Oncol; 2009; 2009():894064. PubMed ID: 20052382
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeted therapy for head and neck cancer: signaling pathways and clinical studies.
    Li Q; Tie Y; Alu A; Ma X; Shi H
    Signal Transduct Target Ther; 2023 Jan; 8(1):31. PubMed ID: 36646686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer stem cells in head and neck cancer.
    Mitra D; Malkoski SP; Wang XJ
    Cancers (Basel); 2011 Jan; 3(1):415-27. PubMed ID: 24212622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments.
    Krause M; Dubrovska A; Linge A; Baumann M
    Adv Drug Deliv Rev; 2017 Jan; 109():63-73. PubMed ID: 26877102
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modern molecular biomarkers of head and neck cancer. Part I. Epigenetic diagnostics and prognostics: Systematic review.
    Juodzbalys G; Kasradze D; Cicciù M; Sudeikis A; Banys L; Galindo-Moreno P; Guobis Z
    Cancer Biomark; 2016; 17(4):487-502. PubMed ID: 27802200
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New insights into RAS in head and neck cancer.
    Jagadeeshan S; Novoplansky OZ; Cohen O; Kurth I; Hess J; Rosenberg AJ; Grandis JR; Elkabets M
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188963. PubMed ID: 37619805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.